No abstract available.
Animals ; Female ; Ovary* ; Rats* ; Serine Proteases* ; Serine*

No abstract available.
Humans* ; Melanocytes* ; Tretinoin*

A new crush anastomosis model which can be evaluated as crush energy was established on the femoral artery and vein of the rats weighing 250g on the average. The degrees of vessel injury were evaluated as crush energy. The arteries underwent the crush injury with the energy of 0.3J, 0.4J, 0.5J, while the reins were crushed with the energy of 0.2J, 0.3J, 0.4J respectively then the vessels in each group were divided and anastomoses by a standard microsurgical technique. Saline and heparin were used as a luminal topical agent and systemic one, which allowed contact with the damaged endothelium. The heparin treated group had a patency rate of 95%(0.3J), 87.5%(0.4J), 40%(0.5J) vs. 55%(0.3J), 15%(0.4J), 10%(0.5J) in the saline irrigated group in the femoral arteries, which had the patency rate of 82.5%(0.2J), 72.5%(0.3J), 42.5%(0.4J) vs. 35%(0.2J), 12.5%(0.3J), 7.5%(0.4J) in the saline irrigated group in the femoral vein at 1 day. There was a energy-related decrease in patency rate. These findings indicate that the crush model of 0.4J in the rat femoral artery, 0.3J in the rat femoral vein is a reliable and reproducible thrombosis model. The model described in this study is to be used to evaluate and assess the ability of antithrombotic agent in preventing thrombosis at the anastomotic site.
Animals ; Arteries ; Endothelium ; Femoral Artery ; Femoral Vein ; Heparin ; Phenobarbital ; Rats* ; Thrombosis ; Veins

PURPOSE: When Managing metastatic bladder tumors, to overcome the resistance mechanism of cisplatin is a main problem to be solved. The objective is to confirm the changes of general and ultrastructural morph ology with the induction of cisplatin resistance from the bladder cell line. MATERIALS AND METHODS: The samples of this investigation are 2ng/ml-cisplatin resistant human bladder cell lines T24R2 established by SNUH Urology and the drug resistant bladder cell lines T24 was obtained from ATCC, as a control group. We cultured the resistant cell line on the slide and observed it using light microscopy to see the general morphology. For the ultrastructural morphology, we fixed cultured cells, made an epon block, sliced an ultrathin section and observed it using H-71000 EM. RESULTS: Under light microscopy, the cytoplasm of the resistant cell line shows a plumper pattern than that of the parent cell. Under electronmicroscopy, the chromatin of the resistant cell line has a relatively finely dispersed chromatin pattern when compared to the parent cell line, which shows a coarse and aggregated chromatin pattern. Within the cytoplasm, the mitochondrial volume, dilated rough endoplasmic reticulum, polyribosomes and ribosomes are moderately increased in the resistant cell line when compared to the parent cell line. In particular, we found a great amount of double membrane vesicle near the cell surface and pinocytic vesicles on the surface, which are seldom observed within the parent cells. CONCLUSIONS: We concluded that the cisplatin resistant human bladder cell lines (T24R2) underwent a morphological change with the induction of cisplatin resistance, and we hypothesize that the resistant cell's ultrastructure, which shows morphological change, will be involved in the drug resistance mechanism. Regarding this matter, further research will be needed.
Cell Line* ; Cells, Cultured ; Chromatin ; Cisplatin* ; Cytoplasm ; Drug Resistance ; Endoplasmic Reticulum, Rough ; Humans ; Membranes ; Microscopy ; Mitochondrial Size ; Parents ; Polyribosomes ; Ribosomes ; Urinary Bladder Neoplasms ; Urinary Bladder* ; Urology

No abstract available.
Compliance* ; Oxygen* ; Positive-Pressure Respiration* ; Respiratory Insufficiency* ; Ventilation*

No abstract available.
Compliance* ; Oxygen* ; Positive-Pressure Respiration* ; Respiratory Insufficiency* ; Ventilation*

No abstract available.
Cartilage* ; Ribs* ; Transplants*

No abstract available.
Kidney Failure, Chronic* ; Tuberculosis*

No abstract available.
Fascia* ; Female* ; Humans ; Urinary Incontinence*

No abstract available.
Transplants*